Rapamune

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Kidney TransplantCognitionAutosomal Dominant Polycystic Kidney DiseaseTuberous Sclerosis

476 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

1

Rapamune

Pfizer

Phase 3

42

Medrol

Pfizer

Preclinical

123

Zinbryta

Roche

Preclinical

64

Zemplar

AbbVie

Preclinical

25

Radicava

Shionogi

Preclinical

16

Cysteine Hydrochloride

Novartis

Preclinical

17

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

18

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

49

Jardiance

Boehringer Ingelheim

Preclinical

310

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2Show 20 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Kidney Transplant4 trials

Study Comparing Cyclosporin Dose Reduction With Cyclosporin Elimination in Kidney Transplant Recipients Taking Sirolimus

Completed·Pfizer·Phase 3·NCT00248313·470 enrolled

Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients

Completed·Pfizer·Phase 4·NCT00044720·484 enrolled

Study Evaluating Sirolimus in Kidney Transplant Recipients in India

Completed·Pfizer·Phase 4·NCT00195481·100 enrolled

Show 1 more trial

Study Evaluating Sirolimus in Kidney Transplant Recipients.

Completed·Pfizer·Phase 3·NCT00167947·150 enrolled

Advanced Solid Cancers1 trial

A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers

Terminated·YYale University·Phase 1·NCT00337376·23 enrolled

Function1 trial

Effect of Rapamycin to Improve Cardiac Function in Frail Older Adults

Completed·MMayo Clinic·Phase 1·NCT04996719·24 enrolled

Renal Transplant Recipients1 trial

Study Comparing Sirolimus/Prograf vs Sirolimus/CsA in High-Risk Renal Transplant Recipients

Completed·Pfizer·Phase 3·NCT00470665·460 enrolled

Autosomal Dominant Polycystic Kidney Disease1 trial

Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Completed·TThe Cleveland Clinic·Phase 1/2·NCT00286156·30 enrolled

8 more indications

Cognition1 trial

Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT04200911·10 enrolled

Tuberous Sclerosis1 trial

Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream

Completed·LLe Bonheur Children's Hospital·Phase 1·NCT01853423·11 enrolled

Renal Allograft Recipients1 trial

Study Comparing Standard Dose and Reduced Dose Tacrolimus + Sirolimus + Corticosteroids in Renal Allograft Recipients

Completed·Pfizer·Phase 2·NCT00518271·120 enrolled

Aged1 trial

Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune)

Recruiting·UUniversity of Nottingham·N/A·NCT05414292·16 enrolled

NPC1 trial

NPC-12G Gel 0.2% Sirolimus PK Bridging Study

Completed·NNobelpharma·Phase 1·NCT03972462·12 enrolled

Renal Transplant1 trial

Study Comparing Standard Dose and Reduced Dose Tacrolimus With Sirolimus in Renal Transplant Patients

Completed·Pfizer·Phase 4·NCT00519116·150 enrolled

Allograft1 trial

Study Comparing Graft Function in Renal Allograft Recepients Receiving Reduced or Standard Dose CsA With Sirolimus

Completed·Pfizer·Phase 4·NCT00518375·250 enrolled

Kidney Biopsy1 trial

Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal

Completed·UUniversity at Buffalo·Phase 4·NCT00896012·58 enrolled

Details

Drug Info

Related News